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Abstract
Purpose The L1 cell adhesion molecule (L1CAM) is consid-
ered a valuable target for therapeutic intervention in different
types of cancer. Recent studies have shown that anti-L1CAM
radioimmunotherapy (RIT) with 67Cu- and 177Lu-labelled
internalising monoclonal antibody (mAb) chCE7 was effec-
tive in the treatment of human ovarian cancer xenografts. In
this study, we directly compared the therapeutic efficacy of
anti-L1CAM RIT against human ovarian cancer under
equitoxic conditions with the radiolanthanide 177Lu and the
potential alternative 161Tb in an ovarian cancer therapy
model.
Methods Tb was produced by neutron bombardment of
enriched 160Gd targets. 161Tb and 177Lu were used for
radiolabelling of DOTA-conjugated antibodies. The in vivo
behaviour of the radioimmunoconjugates (RICs) was assessed
in IGROV1 tumour-bearing nude mice using biodistribution
experiments and SPECT/CT imaging. After ascertaining the
maximal tolerated doses (MTD) the therapeutic impact of
50 %MTD of 177Lu- and 161Tb-DOTA-chCE7 was evaluated
in groups of ten mice by monitoring the tumour size of
subcutaneous IGROV1 tumours.
Results The average number of DOTA ligands per antibody
was 2.5 and maximum specific activities of 600 MBq/mg were
achieved under identical radiolabelling conditions. RICs were
stable in human plasma for at least 48 h. 177Lu- and 161Tb-
DOTA-chCE7 showed high tumour uptake (37.8–39.0 %IA/g,
144 h p.i.) with low levels in off-target organs. SPECT/CT
images confirmed the biodistribution data. 161Tb-labelled
chCE7 revealed a higher radiotoxicity in nude mice (MTD:
10 MBq) than the 177Lu-labelled counterpart (MTD: 12 MBq).
In a comparative therapy study with equitoxic doses, tumour
growth inhibition was better by 82.6 % for the 161Tb-DOTA-
chCE7 than the 177Lu-DOTA-chCE7 RIT.
Conclusions Our study is the first to show that anti-L1CAM
161Tb RIT is more effective compared to 177Lu RIT in ovarian
cancer xenografts. These results suggest that 161Tb is a prom-
ising candidate for future clinical applications in combination
with internalising antibodies.
Keywords 161Tb . 177Lu . Radioimmunotherapy . Ovarian
carcinoma . L1CAM .mAb chCE7
Introduction
Ovarian cancer is a gynaecological malignancy with high
mortality, because it is often diagnosed late. Approximately
75% of the patients will have already developed metastases at
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the time of diagnoses, and debulking surgery is still the crucial
step in ovarian cancer therapy [1]. Some success has been
achieved in the treatment of ovarian cancer during the last
few decades, but the largest percentage of patients will
have a relapse with a median progression-free survival of
18 months [2]. New therapeutic approaches with antibod-
ies and/or selective kinase inhibitors (targeted therapy)
have not made any significant improvement for patients
until now [3, 4]. Overall mortality due to ovarian cancer
remains unchanged, and new therapeutic strategies to
control the disease are very desirable.
The L1 cell adhesion molecule (L1CAM) is a highly gly-
cosylated type I transmembrane protein that is overexpressed
in various tumours and is considered a promising target for
novel therapies (reviewed in: [5–9]). The aberrant expression
of L1CAM is associated with tumour cell invasion and motil-
ity [7], and with poor prognosis and a high risk for progression
in ovarian, uterine, and colorectal cancers [10–12]. The re-
stricted expression of L1CAM in normal tissue [13] has led to
the use of anti-L1CAM monoclonal antibodies in targeted
ovarian cancer therapies [14–17]. To increase the efficacy of
antibody-based L1CAM therapy, we introduced 67Cu [16] and
177Lu [15] for radioimmunotherapy (RIT) in ovarian cancer
therapy models. The choice of the therapeutic low-ß¯-ener-
gy emitting nuclides for RIT matches the size of small
residual disease found after tumour resection in ovarian
cancer patients. The used monoclonal antibody chCE7 is a
chimeric IgG1 molecule that binds with high affinity to
human L1CAM. We could demonstrate that chCE7 binds
near the RGD sequence in the sixth Ig-like domain of human
L1CAM and can prevent the binding to integrins [18]. The
antigen-antibody complex internalised by endocytosis [19]
and metallic radionuclides like 67Cu or 177Lu were trapped
intracellularly. Limiting factors for a more widespread use
of 67Cu in preclinical and clinical evaluations is probably
due to the limited availability of 67Cu and due to the
production-related limited specific activity that can be
reached.
In this study, we directly compared the electron (ß¯) emit-
ters 177Lu and 161Tb for RIT. Both radionuclides are similar
with respect to half-life (6.7 and 6.9 days, respectively), ß¯-
energy (mean 134 keV vs. 154 keV), and chemical properties,
and emit low-energy photons suited for gamma camera imag-
ing. The main difference between these two lanthanides is the
number of emitted conversion and Auger electrons (referred to
as Auger electrons). 161Tb emits 16 times more Auger elec-
trons per decay (3–50 keV) than 177Lu (Table 1).
Auger electrons produce short-range damage that may
have an advantage for the eradication of small tumour nod-
ules. In this study, we compared biodistributions and thera-
peutic anticancer efficacies of 177Lu- and 161Tb-DOTA-
chCE7 immunoconjugates in human ovarian tumour-bearing
nude mice under equitoxic conditions.
Materials and methods
Cell lines and antibodies
IGROV1 human ovarian carcinoma cells were obtained from
Istituto Nazionale per lo Studio e la Cura dei Tumori (Milano,
Italy). Cells were analysed by STR profiling (DSMZ, Braun-
schweig, Germany). Cell culture conditions and antibodies are
described in Supplementary Information (SI).
L1CAM expression on IGROV1 cells
L1CAM expression on IGROV1 cells was analysed by flow
cytometry (SI).
Conjugation of antibodies to DOTA and radiolabelling
Conjugation of antibodies to DOTAwas performed as previ-
ously described [15]. The molar excess of p-SCN-Bn-DOTA
(Macrocyclics, Dallas, TX, USA) was adapted individually
for the different antibodies to achieve a similar number of
DOTA-ligands coupled to the antibodies. The reaction mix-
ture was adjusted to pH 9–10 using a saturated Na3PO4
solution and was incubated overnight (16 h) at 4 °C. Excess
ligands were removed by gel filtration chromatography on a
NAP-5 column (GE Healthcare, Glattbrugg, Switzerland)
which was eluted with 0.25 M ammonium acetate (pH 5.5)
for labelling. The number of chelators coupled per mAb
molecule was determined by mass spectrometry [15].
Immunoconjugates were stored at −80 °C until use.
Carrier-free 161Tb was produced in-house by irradiation of
highly enriched gadolinium-160 targets at the spallation-
induced neutron source at Paul Scherrer Institute (PSI,
Villigen, Switzerland) or at the high-flux nuclear reactor at
the Institut Laue-Langevin (Grenoble, France) and separated
by cation exchange chromatography as described before [20].
177Lu was obtained from ITG (Garching, Munich, Germany).
Both radionuclides were used for radiolabelling according to
published procedures [21]. Briefly, 200–1,000 μg of the
immunoconjugates in a total volume of 500 or 900 μL of
0.25 M ammonium acetate buffer (pH 5.5) was reacted with
100–600 MBq of 177Lu or 161Tb solution at 37 °C for 1 h.
After incubation, EDTAwas added to a final concentration of
5 mmol/L and the mixture was incubated for 5 min to complex
unchelated lutetium or terbium. Purification of the labelled
antibodies was achieved by fast protein liquid chromatogra-
phy (FPLC) size exclusion chromatography on a Superose 12
column (GE Healthcare, Glattbrugg, Switzerland) in phos-
phate buffered saline (PBS) with a flow rate of 0.5 mL/min.
Fractions of 500 μL were collected and the major peak frac-
tions were pooled.
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Quality control of radiolabelled preparations
The immunoreactive fraction of labelled antibody conjugates
was measured by cell-binding assays and data were analysed
according to the Lindmo method [22]. Stability of the labelled
antibodies after incubation in human plasma at 37 °C was
analysed by FPLC size exclusion chromatography on a
TSKgel G3000Wxl column (Tosoh Bioscience, Stuttgart,
Germany) with sodium phosphate buffer (0.3 M NaCl,
0.05 M Na2HPO4, pH 6.2) as mobile phase at a flow rate of
1 mL/min.
Biodistribution and SPECT/CT imaging
Animal studies were conducted in compliance with the Swiss
laws on animal protection. All experiments were approved by
the cantonal committee on animal experiments and permitted
by the responsible cantonal authorities (permission numbers
75528 and 75535). Housing and animal husbandry was con-
ducted according to local law on animal protection. Female
CD1-foxn1nu mice, 4–5 weeks old (Charles River, Sulzfeld,
Germany) were inoculated subcutaneously (right shoulder)
with 7×106 IGROV1 cells and biodistribution studies and
SPECT/CT (NanoSPECT/CT, Bioscan Europe; Paris, France)
imaging were performed 14 days later. For biodistribution
studies 1–3 MBq of 177Lu- or 161Tb-DOTA-chCE7 (30 μg)
was injected into a tail vein of tumour-bearing nude mice and
mice were euthanised at the indicated time points. Tumours
and major organs were collected, weighed, and counted for
radioactivity together with an aliquot of the injected solution
in a gamma counter. Each group with IGROV1 xenografts
consisted of five mice. Results are expressed as percentage of
injected activity per gram (%IA/g). In vivo imaging was done
72 h post i.v. injection of 6 MBq 177Lu-DOTA-chCE7 or
161Tb-DOTA-chCE7 (38 μg) or of 6 MBq isotope matched
177Lu-DOTA control IgG or 161Tb-DOTA control IgG
(38 μg). SPECT data were acquired by Nucline software
(version 1.02, Bioscan, Washington DC, USA). SPECT data
were reconstructed iteratively with HiSPECT software (ver-
sion 1.4.3049, Scivis, Göttingen, Germany). SPECT and CT
data were automatically co-registered as both modalities
shared the same axis of rotation. The fused datasets were
analysed with the InVivoScope postprocessing software (ver-
sion 1.44, Bioscan, Washington DC, USA).
Dose escalation study
Groups of four non-tumour-bearing nude mice (female CD1-
foxn1nu, Charles River, Sulzfeld, Germany) were treated in-
travenously with escalating doses of 177Lu-DOTA-chCE7 (8,
10, 12, and 14 MBq; each 65 μg mAb) or 161Tb-DOTA-
chCE7 (6, 8, 10, and 12 MBq; each 65 μg mAb). After
injection, mice were weighed every other day and monitored
daily for humane endpoint. After 2 weeks, we changed the
inspection intervals to every third day until the end of the
experiment (47 days). The maximum tolerated dose (MTD) is
defined as the first dose level below the dose leading to >20 %
decrease in total body weight in at least one of the mice, or an
early reaching of a defined endpoint of at least one mouse
[23]. Peripheral blood mononuclear cell (PBMC) viability
was analysed 13 days post i.v. injection of RICs in whole
peripheral blood using the Guava ViaCount assay (Guava
Technologies, Cardiff, UK) measured on a guava easyCyte
flow cytometer (Millipore, Zug, Switzerland) according to the
instructions given by the supplier.
Radioimmunotherapy experiments
Based on the results of the dose escalation studies, RIT studies
were performed in female nude mice (eight per group) with
subcutaneous tumours (IGROV1 human ovarian carcinoma,
mean volume 133±50 mm3, 8 days after cell inoculation) and
a 50 %MTD of 177Lu-DOTA-chCE7 or 161Tb-DOTA-chCE7
(30 μg). Equivalently labelled, unspecific matched control
IgGs and PBS were used as controls. All injections were done
i.v. via the lateral tail vein. Tumour growth and the weight of
the mice were evaluated every 2–3 days. Humane endpoint
criteria were defined as weight loss of more than 20 % of the
initial body weight or a tumour volume of more than
1,000 mm3 or ulceration of the tumours. The tumour volume
(V) was calculated using the following equation: V = (L ×
W2)/2, where W is the width of the tumour (small diameter),
and L the length (larger diameter), both in millimetres. The
relative tumour volume (RTV) of each individual tumour was
Table 1 Comparison of the de-
cay properties of 177Lu and 161Tb
Data from: National Nuclear Data
Centre Brookhaven National
Laboratories
Isotope 177Lu 161Tb
Nuclide availability Good Limited
ß¯-energy av/decay (intensity) 134 keV (100 %) 154 keV (100 %)
Conversion and Auger electrons (intensity) 3–50 keV (14 %) 3–50 keV (224 %)
Eγ/EX (intensity) 208 keV (10 %)
113 keV (6 %)
75 keV (10 %)
45–53 keV (39 %)
Half life 6.7 days 6.9 days
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calculated as Vx/Vo (Vx = tumour volume at a given time, Vo
= tumour volume at the start of therapy).
Statistical analysis
Excel software (Microsoft Office 2003) was used for statisti-
cal analyses as described in Supplementary Information.
Results
Conjugation of antibodies to DOTA and labelling
of the conjugates with 177Lu and 161Tb
The average number of ligands per mAb chCE7 was 2.5
determined by mass spectrometry. For the control antibodies
we obtained a similar number of ligands per molecule. For
both radionuclides, 177Lu and 161Tb, maximum specific activ-
ities of 600 MBq/mg antibody have been achieved under
identical reaction conditions.
Aggregates, small fragments, and free radionuclides were
separated from the radiolabelled antibody fraction by FPLC
size exclusion chromatography. The immunoreactivity of the
antibodies analysed by cell binding assays ranged from 78 to
84 %. Both radioimmunoconjugates were stable in human
plasma at 37 °C for at least 48 h. No sign of degradation,
release of radioactivity or aggregation was observed (SI).
Comparative biodistribution of 177Lu-DOTA-chCE7
and 161Tb-DOTA-chCE7
In order to compare the biological behaviour of the DOTA
conjugated chCE7 antibodies in 177Lu- and 161Tb-labelled
form biodistribution experiments were performed on nude
mice with human IGROV1 ovarian carcinoma xenografts.
The L1CAM expression on the cell surface of IGROV cells
was confirmed by FACS analysis (SI). Thirty micrograms of
RICs were injected i.v. and accumulation of radioactivity in all
major organs and tumours was measured (Table 2). Uptake of
radioactivity in tumours was high after 72 h (31.5–33.4 %IA/
g) and increased to 37.8–39.0 %IA/g after 144 h. Both RICs
showed almost identical behaviour in vivo.
SPECT/CT imaging with 177Lu- and 161Tb-DOTA-chCE7
allowed an excellent visualization of implanted L1CAM-
expressing ovarian carcinomas (Fig. 1). Subcutaneous
IGROV1 tumours (7×106 tumour cells, inoculated 14 days
in advance) were visualised with high resolution 72 h after
injection of 6MBq (38 μg) of 177Lu- and 161Tb-labelled RICs.
The images showed low blood activities and low activities in
liver and other organs which leads to the low background. The
labelled unspecific isotope-matched antibodies did not accu-
mulate at the tumour side (Fig. 1b, d).
Determination of the maximum tolerated dose
A direct comparison of the therapeutic effects of 177Lu- and
161Tb-labelled mAb chCE7 can be based on experimentally
determined maximum tolerated dose (MTD). The dose esca-
lation study was done in groups of four non-tumour bearing
nude mice treated with 8, 10, 12, or 14 MBq 177Lu-DOTA-
chCE7 (Fig. 2a) and 6, 8, 10, or 12MBq 161Tb-DOTA-chCE7
(Fig. 2b). The amount of the injected RICs was adjusted to
65 μg. Within the first 10 days, one mouse died unexpectedly
in the 12MBq 177Lu-DOTA-chCE7 group. This death was not
regarded as related to the application of the RIC (no signs of
distress, no change in behaviour, and no radiation syndrome),
and therefore, it was not taken into the evaluation.
Twelve to 14 days after administration of the highest dose
of radioactivity (14 MBq of 177Lu-labelled and 12 MBq of
161Tb-labelled immunoconjugate) we observed a significant
decrease in body weight for almost all mice in these treatment
groups (Fig. 2a, b). The mice looked pale; their agility
dropped, and mice showed signs of distress and acute radia-
tion syndrome. A representative picture of such a mouse is
shown in (SI). At the same time, the number of red blood cells
Table 2 Biodistribution of 177Lu- and 161Tb-labelled antibody chCE7 in
nude mice with subcutaneous ovarian cancer (IGROV1)
177Lu-DOTA-chCE7
Organ (%IA/g) 72 h 144 h*
Tumour 33.4±7.7 37.8±1.5
Blood 10.4±2.5 8.7±0.9
Liver 6.8±1.4 6.6±1.5
Spleen 7.0±1.7 7.5±2.2
Kidney 3.4±0.8 2.8±0.2
Heart 4.6±1.2 3.7±0.3
Stomach 0.6±0.1 0.6±0.1
Intestine 0.8±0.1 0.9±0.2
Muscle 1.5±0.5 1.7±0.5
Bone 1.6±0.3 1.7±0.4
161Tb-DOTA-chCE7
Organ (%IA/g) 72 h 144 h
Tumour 31.5±8.5 39.0±13.1
Blood 8.2±3.8 7.0±4.6
Liver 6.7±1.2 6.6±1.4
Spleen 7.7±2.9 8.9±5.0
Kidney 3.1±0.6 2.6±0.9
Heart 3.7±1.5 3.1±1.6
Stomach 0.4±0.1 0.3±0.1
Intestine 1.1±0.1 0.9±0.1
Muscle 0.9±0.3 0.7±0.3
Bone 2.0±0.4 1.5±0.3
Groups of five (*four) animals were injected i.v. with 1.0 MBq (30 μg) of
177 Lu-DOTA-chCE7 or 1.5 MBq (30 μg) of 161 Tb-DOTA-chCE7. Data
are presented as %IA/g ± SD
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and the viability of the peripheral white blood cells dropped
(Table 3). The MTD for the 177Lu-labelled compound was
found to be higher (12 MBq) compared to the 161Tb-labelled
compound (10 MBq).
Comparative therapy study of 177Lu-DOTA-chCE7
and 161Tb-DOTA-chCE7
An experiment comparing the therapeutic efficacy of anti-
L1CAM RIT using 177Lu-DOTA-chCE7 and 161Tb-DOTA-
chCE7 was performed in nude mice with subcutaneous tu-
mour xenografts (IGROV1 human ovarian carcinoma, mean
volume 133±50 mm3, 8 days after cell inoculation).
Radiolabelled antibodies were injected i.v. A 50%MTD dose
of 161Tb-DOTA-chCE7 (5 MBq) induced prominent tumour
growth retardation compared with mice that received corre-
sponding control treatments (Fig. 3). The effect of 50 %MTD
of 177Lu-DOTA-chCE7 (6 MBq) was less prominent. After a
short delay phase, the mean relative tumour volume (RTV) in
all control groups increased roughly linearly and increased
three times compared to therapy started after a tumour growth
delay (TGD) of 40 days (in the case of 161Tb-DOTA-unspe-
cific matched control IgG), 47 days (in the case of 177Lu-
DOTA-unspecific matched control IgG) and 54 days (in the
case of PBS). In both anti-L1CAM targeted therapy groups, a
mean three-fold increase of the start RTV was not reached,
because the first mouse in these groups attained the endpoint
before. Therefore, we calculated the TGD in these groups with
a RTVincrease of 2.3 for 177Lu-DOTA-chCE7 (TGD 69 days)
and a RTV increase of 2.5 for 161Tb-DOTA-chCE7 (TGD
118 days). This fact underestimates the tumour growth delay
for both therapies.
The average RTV was reduced significantly in the targeted
177Lu- and 161Tb-DOTA-chCE7 therapy groups compared to
all controls (p-values 0.004 to <0.00001). The average RTV
dropped significantly (p<0.05) in the 161Tb-RIT group com-
pared to the 177Lu-RIT group. A tumour growth inhibition
(TGI) of 67.5–85.7 % was obtained for 177Lu anti-L1CAM
RIT and was higher than 94 % for the 161Tb-RIT in compar-
ison to control treatments. The TGI of 161Tb-RITwas better by
82.6 % compared to 177Lu-RIT.
Discussion
In this study, we investigated the efficacy of anti-L1CAM
radioimmunotherapy using mAb chCE7 labelled with 177Lu
or 161Tb. For both radiolanthanides, we used the same label-
ling procedures and obtained stable radiolabelled DOTA con-
jugated antibodies with high specif ic activit ies.
Biodistribution studies showed that both radioconjugates dis-
tributed similarly in tumour-bearing nude mice. The immuno-
reactivity of both radioconjugates was equal. Terbium and
lutetium have similar ionic radii (Tb: 0.923 Å; Lu: 0. 861 Å)
for six-coordinate complexes [24, 25], and both lanthanides
build extremely stable complexes with DOTA ligands [26],
which is reflected in the low uptake of radioactivity in bones.
It has been described that nude mice exhibit often-different
endogenous IgG concentrations that can influence blood pool,
spleen and liver uptake of injected mAbs [27, 28]. To
Fig. 1 Whole-body SPECT/CT
imaging of tumour-bearing nude
mice. The images were taken 72 h
after i.v. injection of six MBq
radioimmunoconjugates (38 μg).
a 177Lu-DOTA-chCE7, b 177Lu-
DOTA-matched-control IgG, c
161Tb-DOTA-chCE7, d 161Tb-
DOTA-matched-control IgG. The
mice are had one IGROV1
tumour on the right shoulder
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compensate for most of these effects we injected 30 μg IgG
per mouse in the biodistribution experiments. We cannot
exclude that such effects influenced the biodistribution of
177Lu-DOTA-chCE7 in one mouse at 144 h post injection.
The mouse showed unusually low activity in tumour and
organs (SI). We assume that this low activity was due to a
small amount of administered antibody. This mouse was not
considered for statistical analysis. The clear SPECT/CT im-
ages confirmed the biodistributions we obtained for both
radioconjugates. Therefore, both radiolanthanides are suitable
Fig. 2 Dose escalation studies
with a 177Lu-DOTA-chCE7 or b
161Tb-DOTA-chCE7 in nude
mice. Mice were injected i.v. with
increasing doses of 177Lu- or
161Tb-labelled antibody chCE7
(n=4 per dose). The amounts of
injected antibodies were constant
at 65 μg for each dose. Body-
weight and health of mice were
monitored for 47 days. The
maximum tolerated dose was
12 MBq for 177Lu-DOTA-chCE7
and 10 MBq for 161Tb-DOTA-
chCE7
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in the sameway for imaging in small animals. The low gamma
ray energies of 161Tb may limit the clinical application for
diagnostic purposes.
For direct comparison of the therapeutic efficacy of the
177Lu- or 161Tb-labelled chCE7 antibodies, we determined the
MTD for both radioimmunoconjugates. Tumour-free mice
were chosen for the dose escalation study to simulate the worst
case, i.e. no tumour accumulation of the antibody. Conse-
quently, the RICs follow their biological half-life in blood
and distribute without accumulation at a tumour site in the
body. For the dose escalation study we used 65 μg of labelled
antibody per mouse (resulting from the highest dose that was
given) to exclude the influence of endogenous IgG concen-
trations and to hold the conditions for the whole dose range
constant. The higher radiotoxicity of mAb 161Tb-DOTA-
chCE7 (MTD: 10 MBq) compared to 177Lu-DOTA-chCE7
(MTD: 12 MBq) is certainly caused in part by the higher ß¯
energy emitted by 161Tb. This is in agreement with observa-
tions of Brouwers et al. [29] who found a low MTD of
5.6 MBq for a 90Y-labelled internalising chimeric antibody
in nude mice. Yttrium-90 has mean ß¯ energy of 900 keV. It is
most likely that the additional Auger and conversion electrons
emitted by 161Tb influenced the radiotoxicity too. The short-
range electrons exert their greatest toxicity effects only after
internalisation or on the cell membrane of the target cell
[30–33]. Inside the cell, Auger electrons are able to deposit
high energy around the decay site which leads to ionisation
and excitations, chemical transmutations, local effects of
charged species, and nuclear recoil [30, 34]. The biological
effects induced by Auger electrons are, for the most part,
indirectly caused [30]. The significance of intracellular posi-
tion near the cell nucleus has been discussed [30, 34–36]. In
this context, the group of Reilly reported that nuclear localiz-
ing sequences coupled to an 111In-labelled antibody promoted
specific nuclear uptake in tumour cells and enhanced the
radiotoxicity of the antibody [37, 38]. On the other hand,
Guo et al. [39] showed that an increased nuclear uptake of
the Auger emitter 64Cu in a radioimmunotherapy regime of
HCT116 tumour-bearing nude mice had no advantage. In this
comparative RIT study between 177Lu- and 161Tb-labelled
monoclonal antibodies using 50 % MTD we could clearly
demonstrate that the 161Tb-labelled mAb chCE7 performed
much better than the 177Lu-labelled counterpart. The differ-
ences were significant and tumour growth inhibition was
82.6 % higher for 161Tb-DOTA-chCE7 vs. 177Lu-DOTA-
chCE7. We assume that the better therapeutic efficacy of
161Tb-RIT is the result of both the higher ß¯ energy and the
16-fold higher emission rate of conversion and Auger elec-
trons. More than half of these electrons (3–50 keV) emitted by
161Tb have an energy higher than 16 keV. This could explain
why a nuclear localization is not necessary for the great effect
of 161Tb. It is known that Auger electrons induce bystander
effects, which can harm neighbouring cells [40]. This may
Table 3 Peripheral blood mono-
nuclear cell (PBCM) viability in
tumour-free nude mice after
treatment with increasing doses of
radiolabelled antibodies (n=4/
dose)
Blood samples were analysed
13 days post i.v. injection of RICs
a Less than 160 nucleated cells
were counted (normally 1,000 nu-
cleated cells were counted)
Viable [% of total] Apoptotic [% of total] Dead [% of total] Total
[%]
Control 99.0 <1.0 <1.0 100
8 MBq 177Lu-DOTA-chCE7 95.3 4.0 0.7 100
10 MBq 177Lu-DOTA-chCE7 83.1 14.0 2.9 100
12 MBq 177Lu-DOTA-chCE7 83.8 14.6 1.6 100
14 MBq 177Lu-DOTA-chCE7a 48.7 43.5 7.8 100
6 MBq 161Tb-DOTA-chCE7 97.7 2.0 0.3 100
8 MBq 161Tb-DOTA-chCE7 94.2 5.6 0.2 100
10 MBq 161Tb-DOTA-chCE7 96.7 3.3 0.0 100
12 MBq 161Tb-DOTA-chCE7a 40.2 39.4 20.4 100
Fig. 3 Therapeutic efficacy of 177Lu- and 161Tb-DOTA-chCE7 RIT in
nude mice bearing subcutaneous IGROV1 tumours. Tumour-bearing
nude mice were treated i.v. with 50 % MTD of 177Lu- or 161Tb-labelled
anti-L1CAM mAb chCE7 or labelled control antibodies or PBS. Data
represent the mean relative tumour volumes ± SD. Tumour growth curves
were stopped when the first tumour in a treatment group reached
1,000 mm3. The dashed line represents a three-fold increase of the
RTV. The dotted lines represent a) a 2.3-fold increase of the RTV (for
the 177Lu-DOTA chCE7 treatment) or b) a 2.5-fold increase of the RTV
(for the 161Tb-DOTA-chCE7 treatment)
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also have influenced the therapeutic efficacy of the RIT. At
present, dosimetric estimations are not able to reflect all ra-
diobiological responses induced by conversion and Auger
electrons [35].
Conclusions
Our study is, to our knowledge, the first to show that 161Tb-
RIT is more effective in an ovarian cancer model under
equitoxic conditions in comparison to 177Lu-RIT. For both
radiolanthanides the same well established chemistry can be
used and biodistributions of the RICs were similar. The 161Tb-
labelled antibody showed a slightly higher radiotoxicity in a
dose escalation study compared to the 177Lu-labelled mAb.
Overall, 161Tb is potentially the better candidate for RIT with
internalisation antibodies. Next, we will investigate if we can
optimise the RIT with 161Tb in combination with
radiosensitising agents, and we will analyse the exact molec-
ular mechanisms of the radiobiological effects induced by the
Auger electrons.
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